Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma von Algazi, A P, Weber, J S, Andrews, S C, Urbas, P, Munster, P N, DeConti, R C, Hwang, J, Sondak, V K, Messina, J L, McCalmont, T, Daud, A I

Volltext

Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial von Chan, A.T.C., Lee, V.H.F., Hong, R.-L., Ahn, M.-J., Chong, W.Q., Kim, S.-B., Ho, G.F., Caguioa, P.B., Ngamphaiboon, N., Ho, C., Aziz, M.A.S.A., Ng, Q.S., Yen, C.-J., Soparattanapaisarn, N., Ngan, R.K.-C., Kho, S.K., Tiambeng, M.L.A., Yun, T., Sriuranpong, V., Algazi, A.P., Cheng, A., Massarelli, E., Swaby, R.F., Saraf, S., Yuan, J., Siu, L.L.

Volltext

Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma von DeConti, R C, Algazi, A P, Andrews, S, Urbas, P, Born, O, Stoeckigt, D, Floren, L, Hwang, J, Weber, J, Sondak, V K, Daud, A I

Volltext

The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II... von Algazi, A P, Cha, E, Ortiz-Urda, S M, McCalmont, T, Bastian, B C, Hwang, J, Pampaloni, M H, Behr, S, Chong, K, Cortez, B, Quiroz, A, Coakley, F, Liu, S, Daud, A I

Volltext

A phase II clinical/translational trial of sequential axitinib/carboplatin/paclitaxel in melanoma von Algazi, A. P., Cha, E., Soon, C., Ortiz-Urda, S., Cortez, B., Ziani, L., Coakley, F. V., Daud, A.

Volltext

A phase I/II trial of DTIC and dasatinib in metastatic melanoma von Algazi, A. P., Weber, J. S., Andrews, S., Urbas, P., Arimura, E., Hwang, J., Sondak, V. K., Bastian, B., Daud, A.

Volltext

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study von Cohen, Ezra E W, Soulières, Denis, Le Tourneau, Christophe, Dinis, José, Licitra, Lisa, Ahn, Myung-Ju, Soria, Ainara, Mach, Nicolas, Mehra, Ranee, Burtness, Barbara, Zhang, Pingye, Cheng, Jonathan, Swaby, Ramona F, Acosta-Rivera, Mirelis, Adkins, Douglas R., Aghmesheh, Morteza, Ahn, Myung-Ju, Airoldi, Mario, Aleknavicius, Eduardas, Al-Farhat, Yousuf, Algazi, Alain P., Almokadem, Salah, Alyasova, Anna, Bauman, Jessica R., Benasso, Marco, Berrocal, Alfonso, Bray, Victoria, Burtness, Barbara Ann, Caponigro, Francesco, Castro, Ana, Cescon, Terrence P., Chan, Kelvin, Chaudhry, Arvind, Chauffert, Bruno, Cohen, Ezra, De Boer, J.P., Dietz, Andreas, Dinis, Jose, Dupuis, Charlotte, Digue, Laurence, Escobar Alvarez, Yolanda, Evans, Mererid, Fidler, Mary Jo, Forster, Martin David, Friesland, Signe, Ganti, Apar K., Geoffrois, Lionnel, Grant, Cliona, Gruenwald, Viktor, Harrington, Kevin, Horvai, Geza, Inciura, Arturas, Jang, Raymond, Jankowska, Petra, Jimeno, Antonio, Joseph, Mano, Juarez Ramiro, Alejandro, Karaszewska, Boguslawa, Kawecki, Andrzej, Keilholz, Ulrich, Keller, Ulrich, Kocsis, Judit, Kotecki, Nuria, Kozloff, Mark F., Lambea, Julio, Landherr, Laszlo, Lantsukhay, Yuri, Lazarev, Sergey Alexandrovich, Lee, Lip Way, Le Tourneau, Christophe, Licitra, Lisa, Martincic, Danko, Matorin, Oleg Vladmirovhich, McGrath, Margaret, Machiels, Jean-Pascal, Mehra, Ranee, Misiukiewicz, Krzysztof, Morris, John C., Mufazalov, Fagim Fanisovich, Niu, Jiaxin, Pamoorthy Srinivasan, Devraj, Perez Segura, Pedro, Rauch, Daniel, Ribeiro, Maria Leonor, Rodriguez, Cristina, Rolland, Frederic, Russo, Antonio, Ruzsa, Agnes, Sanches, Frederico, Shin, Sang-Won, Shtiveland, Mikhail, Soulieres, Denis, Specenier, Pol, van Herpen, Carla M.L., Velez-Cortes, Hector A., Walsh, William V., Winterhalder, Ralph, Wojtukiewicz, Marek, Wong, Deborah, Zandberg, Dan

Volltext

Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma : Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have... von Zandberg, D. P, Algazi, A. P, Jimeno, A, Good, J. S, Fayette, J, Bouganim, N, Ready, N. E, Clement, P. M, Even, C, Jang, R. W, Wong, S, Keilholz, Ulrich, Gilbert, J, Fenton, M, Braña, Irene, Henry, S, Remenar, E, Papai, Z, Siu, L. L, Jarkowski, A, Armstrong, Jon M, Asubonteng, K, Fan, J, Melillo, G, Mesía, R, Universitat Autònoma de Barcelona

Volltext bestellen

The efficacy of anti‐PD‐1 agents in acral and mucosal melanoma von Shoushtari, Alexander N., Munhoz, Rodrigo R., Kuk, Deborah, Ott, Patrick A., Johnson, Douglas B., Tsai, Katy K., Rapisuwon, Suthee, Eroglu, Zeynep, Sullivan, Ryan J., Luke, Jason J., Gangadhar, Tara C., Salama, April K. S., Clark, Varina, Burias, Clare, Puzanov, Igor, Atkins, Michael B., Algazi, Alain P., Ribas, Antoni, Wolchok, Jedd D., Postow, Michael A.

Volltext

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain von Tawbi, Hussein A, Forsyth, Peter A, Algazi, Alain, Hamid, Omid, Hodi, F. Stephen, Moschos, Stergios J, Khushalani, Nikhil I, Lewis, Karl, Lao, Christopher D, Postow, Michael A, Atkins, Michael B, Ernstoff, Marc S, Reardon, David A, Puzanov, Igor, Kudchadkar, Ragini R, Thomas, Reena P, Tarhini, Ahmad, Pavlick, Anna C, Jiang, Joel, Avila, Alexandre, Demelo, Sheena, Margolin, Kim

Volltext

Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma von Daud, Adil I, Loo, Kimberly, Pauli, Mariela L, Sanchez-Rodriguez, Robert, Sandoval, Priscila Munoz, Taravati, Keyon, Tsai, Katy, Nosrati, Adi, Nardo, Lorenzo, Alvarado, Michael D, Algazi, Alain P, Pampaloni, Miguel H, Lobach, Iryna V, Hwang, Jimmy, Pierce, Robert H, Gratz, Iris K, Krummel, Matthew F, Rosenblum, Michael D

Volltext

Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy von Wang, Yujue, Liu, Sixue, Yang, Zhentao, Algazi, Alain P., Lomeli, Shirley H., Wang, Yan, Othus, Megan, Hong, Aayoung, Wang, Xiaoyan, Randolph, Chris E., Jones, Alexis M., Bosenberg, Marcus W., Byrum, Stephanie D., Tackett, Alan J., Lopez, Henry, Yates, Clayton, Solit, David B., Ribas, Antoni, Piva, Marco, Moriceau, Gatien, Lo, Roger S.

Volltext

Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12 von Garris, Christopher S., Arlauckas, Sean P., Kohler, Rainer H., Trefny, Marcel P., Garren, Seth, Piot, Cécile, Engblom, Camilla, Pfirschke, Christina, Siwicki, Marie, Gungabeesoon, Jeremy, Freeman, Gordon J., Warren, Sarah E., Ong, SuFey, Browning, Erica, Twitty, Christopher G., Pierce, Robert H., Le, Mai H., Algazi, Alain P., Daud, Adil I., Pai, Sara I., Zippelius, Alfred, Weissleder, Ralph, Pittet, Mikael J.

Volltext

Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy von Nosrati, Adi, Tsai, Katy K, Goldinger, Simone M, Tumeh, Paul, Grimes, Barbara, Loo, Kimberly, Algazi, Alain P, Nguyen-Kim, Thi Dan Linh, Levesque, Mitchell, Dummer, Reinhard, Hamid, Omid, Daud, Adil

Volltext

Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre... von Tawbi, Hussein A, Forsyth, Peter A, Hodi, F Stephen, Algazi, Alain P, Hamid, Omid, Lao, Christopher D, Moschos, Stergios J, Atkins, Michael B, Lewis, Karl, Postow, Michael A, Thomas, Reena P, Glaspy, John, Jang, Sekwon, Khushalani, Nikhil I, Pavlick, Anna C, Ernstoff, Marc S, Reardon, David A, Kudchadkar, Ragini, Tarhini, Ahmad, Chung, Caroline, Ritchings, Corey, Durani, Piyush, Askelson, Margarita, Puzanov, Igor, Margolin, Kim A

Volltext

Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes von Rahim, Maha K., Okholm, Trine Line H., Jones, Kyle B., McCarthy, Elizabeth E., Liu, Candace C., Yee, Jacqueline L., Tamaki, Stanley J., Marquez, Diana M., Tenvooren, Iliana, Wai, Katherine, Cheung, Alexander, Davidson, Brittany R., Johri, Vrinda, Samad, Bushra, O’Gorman, William E., Krummel, Matthew F., van Zante, Annemieke, Combes, Alexis J., Angelo, Michael, Fong, Lawrence, Algazi, Alain P., Ha, Patrick, Spitzer, Matthew H.

Volltext

Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have... von Zandberg, Dan P., Algazi, Alain P., Jimeno, Antonio, Good, James S., Fayette, Jérôme, Bouganim, Nathaniel, Ready, Neal E., Clement, Paul M., Even, Caroline, Jang, Raymond W., Wong, Stuart, Keilholz, Ulrich, Gilbert, Jill, Fenton, Moon, Braña, Irene, Henry, Stephanie, Remenar, Eva, Papai, Zsuzsanna, Siu, Lillian L., Jarkowski, Anthony, Armstrong, Jon M., Asubonteng, Kobby, Fan, Jean, Melillo, Giovanni, Mesía, Ricard

Volltext

Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma von Algazi, Alain P., Twitty, Christopher G., Tsai, Katy K., Le, Mai, Pierce, Robert, Browning, Erica, Hermiz, Reneta, Canton, David A., Bannavong, Donna, Oglesby, Arielle, Francisco, Murray, Fong, Lawrence, Pittet, Mikael J., Arlauckas, Sean P., Garris, Christopher, Levine, Lauren P., Bifulco, Carlos, Ballesteros-Merino, Carmen, Bhatia, Shailender, Gargosky, Sharron, Andtbacka, Robert H. I., Fox, Bernard A., Rosenblum, Michael D., Daud, Adil I.

Volltext

Clinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodies von Algazi, Alain P., Tsai, Katy K., Shoushtari, Alexander N., Munhoz, Rodrigo R., Eroglu, Zeynep, Piulats, Josep M., Ott, Patrick A., Johnson, Douglas B., Hwang, Jimmy, Daud, Adil I., Sosman, Jeffrey A., Carvajal, Richard D., Chmielowski, Bartosz, Postow, Michael A., Weber, Jeffrey S., Sullivan, Ryan J.

Volltext

Treatment modality impact on quality of life for human papillomavirus–associated oropharynx cancer von Xu, Mary Jue, Plonowska, Karolina A., Gurman, Zev R., Humphrey, Amanda K., Ha, Patrick K., Wang, Steven J., El‐Sayed, Ivan H., Heaton, Chase M., George, Jonathan R., Yom, Sue S., Algazi, Alain P., Ryan, William R.

Volltext